Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADVANCE CAPACITY: Ralinepag in Pulmonary Arterial Hypertension
NCT04084678Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Jan 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of ralinepag in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Jan 2021; status: terminated.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04084678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084678.